S&P 500   4,290.20 (+0.23%)
DOW   33,869.42 (+0.32%)
QQQ   331.38 (+0.30%)
AAPL   172.64 (+0.31%)
MSFT   291.92 (+0.00%)
META   180.35 (-0.08%)
GOOGL   121.54 (-0.12%)
AMZN   142.36 (-0.83%)
TSLA   923.26 (+2.57%)
NVDA   188.32 (+0.66%)
NIO   21.13 (+0.09%)
BABA   94.06 (-0.75%)
AMD   100.77 (-0.06%)
MU   64.39 (-1.00%)
T   18.37 (+0.55%)
CGC   3.71 (+12.42%)
GE   79.34 (-0.74%)
F   16.25 (+0.43%)
DIS   124.78 (+2.64%)
AMC   23.89 (-2.25%)
PYPL   101.52 (+0.42%)
PFE   49.47 (-1.28%)
NFLX   250.02 (+0.29%)
S&P 500   4,290.20 (+0.23%)
DOW   33,869.42 (+0.32%)
QQQ   331.38 (+0.30%)
AAPL   172.64 (+0.31%)
MSFT   291.92 (+0.00%)
META   180.35 (-0.08%)
GOOGL   121.54 (-0.12%)
AMZN   142.36 (-0.83%)
TSLA   923.26 (+2.57%)
NVDA   188.32 (+0.66%)
NIO   21.13 (+0.09%)
BABA   94.06 (-0.75%)
AMD   100.77 (-0.06%)
MU   64.39 (-1.00%)
T   18.37 (+0.55%)
CGC   3.71 (+12.42%)
GE   79.34 (-0.74%)
F   16.25 (+0.43%)
DIS   124.78 (+2.64%)
AMC   23.89 (-2.25%)
PYPL   101.52 (+0.42%)
PFE   49.47 (-1.28%)
NFLX   250.02 (+0.29%)
S&P 500   4,290.20 (+0.23%)
DOW   33,869.42 (+0.32%)
QQQ   331.38 (+0.30%)
AAPL   172.64 (+0.31%)
MSFT   291.92 (+0.00%)
META   180.35 (-0.08%)
GOOGL   121.54 (-0.12%)
AMZN   142.36 (-0.83%)
TSLA   923.26 (+2.57%)
NVDA   188.32 (+0.66%)
NIO   21.13 (+0.09%)
BABA   94.06 (-0.75%)
AMD   100.77 (-0.06%)
MU   64.39 (-1.00%)
T   18.37 (+0.55%)
CGC   3.71 (+12.42%)
GE   79.34 (-0.74%)
F   16.25 (+0.43%)
DIS   124.78 (+2.64%)
AMC   23.89 (-2.25%)
PYPL   101.52 (+0.42%)
PFE   49.47 (-1.28%)
NFLX   250.02 (+0.29%)
S&P 500   4,290.20 (+0.23%)
DOW   33,869.42 (+0.32%)
QQQ   331.38 (+0.30%)
AAPL   172.64 (+0.31%)
MSFT   291.92 (+0.00%)
META   180.35 (-0.08%)
GOOGL   121.54 (-0.12%)
AMZN   142.36 (-0.83%)
TSLA   923.26 (+2.57%)
NVDA   188.32 (+0.66%)
NIO   21.13 (+0.09%)
BABA   94.06 (-0.75%)
AMD   100.77 (-0.06%)
MU   64.39 (-1.00%)
T   18.37 (+0.55%)
CGC   3.71 (+12.42%)
GE   79.34 (-0.74%)
F   16.25 (+0.43%)
DIS   124.78 (+2.64%)
AMC   23.89 (-2.25%)
PYPL   101.52 (+0.42%)
PFE   49.47 (-1.28%)
NFLX   250.02 (+0.29%)
NASDAQ:AMED

Amedisys - AMED Stock Forecast, Price & News

$122.16
-0.20 (-0.16%)
(As of 08/15/2022 11:44 AM ET)
Add
Compare
Today's Range
$120.69
$124.04
50-Day Range
$105.12
$131.14
52-Week Range
$101.61
$188.88
Volume
3,431 shs
Average Volume
372,216 shs
Market Capitalization
$3.96 billion
P/E Ratio
28.48
Dividend Yield
N/A
Price Target
$158.53

Amedisys MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
30.1% Upside
$158.53 Price Target
Short Interest
Healthy
5.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.28mentions of Amedisys in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$64,055 Sold Last Quarter
Proj. Earnings Growth
11.42%
From $5.34 to $5.95 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.06 out of 5 stars

Medical Sector

21st out of 1,128 stocks

Home Health Care Services Industry

1st out of 9 stocks

AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Amedisys Price Performance

Amedisys stock opened at $122.36 on Monday. The business has a 50 day simple moving average of $118.97 and a 200-day simple moving average of $134.30. The stock has a market capitalization of $3.97 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 2.95 and a beta of 0.95. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.92 and a quick ratio of 0.92. Amedisys has a 12 month low of $101.61 and a 12 month high of $188.88.

Amedisys (NASDAQ:AMED - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.24. The firm had revenue of $557.89 million during the quarter, compared to analysts' expectations of $583.12 million. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. Amedisys's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.69 earnings per share. Equities analysts predict that Amedisys will post 5.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on AMED shares. Deutsche Bank Aktiengesellschaft dropped their target price on Amedisys from $210.00 to $175.00 and set a "buy" rating for the company in a research report on Tuesday, June 21st. Raymond James lowered their price objective on Amedisys from $200.00 to $180.00 in a research report on Friday, April 29th. Jefferies Financial Group reissued a "buy" rating and set a $200.00 price objective on shares of Amedisys in a research report on Tuesday, June 28th. Truist Financial lowered their price objective on Amedisys from $175.00 to $150.00 and set a "buy" rating for the company in a research report on Thursday, July 14th. Finally, Bank of America downgraded Amedisys from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $145.00 to $102.00 in a research report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $158.53.

Insiders Place Their Bets

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of the stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total value of $64,055.00. Following the completion of the transaction, the insider now owns 11,850 shares in the company, valued at $1,362,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

Amedisys (NASDAQ:AMED) Stock Rating Lowered by UBS Group
Amedisys, Inc. (NASDAQ:AMED) Short Interest Up 24.6% in July
Amedisys (NASDAQ:AMED) Price Target Cut to $175.00
Amedisys (NASDAQ:AMED) PT Lowered to $165.00
Amedisys (NASDAQ:AMED) Shares Gap Down on Analyst Downgrade
Amedisys: Q2 Earnings Snapshot - Greenwich Time
Amedisys (AMED) Q2 Earnings Beat Estimates
Amedisys (AMED) Scheduled to Post Earnings on Wednesday
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
7/27/2022
Today
8/15/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$158.53
High Stock Price Forecast
$213.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+29.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

Net Income
$209.07 million
Pretax Margin
8.44%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$8.22 per share
Book Value
$29.95 per share

Miscellaneous

Free Float
31,762,000
Market Cap
$3.96 billion
Optionable
Optionable
Beta
0.95

Social Links















AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMED shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2022?

16 analysts have issued 1 year price objectives for Amedisys' stock. Their AMED share price forecasts range from $95.00 to $213.00. On average, they anticipate the company's share price to reach $158.53 in the next year. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2022?

Amedisys' stock was trading at $161.88 on January 1st, 2022. Since then, AMED shares have decreased by 24.4% and is now trading at $122.36.
View the best growth stocks for 2022 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Wednesday, July, 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.24. The health services provider had revenue of $557.89 million for the quarter, compared to analyst estimates of $583.12 million. Amedisys had a trailing twelve-month return on equity of 17.81% and a net margin of 6.33%. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.69 EPS.

How will Amedisys' stock buyback program work?

Amedisys announced that its board has initiated a share repurchase program on Wednesday, August 4th 2021, which authorizes the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $5.23-$5.45 for the period, compared to the consensus earnings per share estimate of $5.30. The company issued revenue guidance of $2.29 billion-$2.31 billion, compared to the consensus revenue estimate of $2.35 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (5.20%), Riverbridge Partners LLC (5.15%), Mackenzie Financial Corp (3.10%), Ensign Peak Advisors Inc (1.76%), Credit Suisse AG (1.57%) and Allspring Global Investments Holdings LLC (1.33%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $122.36.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $3.97 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $4.29 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.